



# HHS Public Access

Author manuscript

*Sci Transl Med.* Author manuscript; available in PMC 2024 April 17.

Published in final edited form as:

*Sci Transl Med.* 2023 June 21; 15(701): eabq7839. doi:10.1126/scitranslmed.abq7839.

## An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor

Oscar E. Reyes Gaido<sup>1,†</sup>, Nikoleta Pavlaki<sup>2,†</sup>, Jonathan M. Granger<sup>1</sup>, Olurotimi O. Mesubi<sup>1</sup>, Bian Liu<sup>3</sup>, Brian L. Lin<sup>1</sup>, Alan Long<sup>4</sup>, David Walker<sup>2</sup>, Joshua Mayourian<sup>2</sup>, Kate L. Schole<sup>1</sup>, Chantelle E. Terrillion<sup>5</sup>, Lubika J. Nkashama<sup>1</sup>, Mohit M. Hulsurkar<sup>6</sup>, Lauren E. Dorn<sup>6</sup>, Kimberly M. Ferrero<sup>1</sup>, Richard L. Haganir<sup>3</sup>, Frank U. Müller<sup>7</sup>, Xander H. T. Wehrens<sup>6,8</sup>, Jun O. Liu<sup>4</sup>, Elizabeth D. Luczak<sup>1</sup>, Vassilios J. Bezzerides<sup>2,\*</sup>, Mark E. Anderson<sup>1,9,\*</sup>

<sup>1</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

<sup>2</sup>Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.

<sup>3</sup>Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

<sup>4</sup>Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

<sup>5</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

<sup>6</sup>Cardiovascular Research Institute and Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.

<sup>7</sup>Institute of Pharmacology and Toxicology, University of Münster, Münster 48149, Germany.

<sup>8</sup>Departments of Medicine, Neuroscience, and Pediatrics, Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

<sup>9</sup>Division of Biological Sciences and the Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.

### Abstract

American Association for the Advancement of Science. No claim to original U.S. Government Works

\*Corresponding author. vassilios.bezzerides@cardio.chboston.org (V.J.B.); andersonm1@bsd.uchicago.edu (M.E.A.).

†These authors contributed equally to this work.

**Author contributions:** O.E.R.G. and M.E.A. conceptualized the study. O.E.R.G., N.P., and V.J.B. created the original draft of the manuscript. O.E.R.G., N.P., M.E.A., and V.J.B. reviewed and edited the final manuscript. O.E.R.G., N.P., A.L., B.L.L., F.U.M., R.L.H., X.H.T.W., and J.O.L. developed the methodology. O.E.R.G., N.P., J.M.G., L.J.N., D.W., J.M., C.E.T., O.O.M., K.L.S., B.L., M.M.H., L.E.D., K.M.F., E.D.L., and V.J.B. carried out the experimental studies. O.E.R.G. and N.P. created visual representations of the data.

**Competing interests:** O.E.R.G., E.D.L., and M.E.A. are authors on two provisional patents [Inhibitors of calcium/calmodulin-dependent protein kinase II and their uses (#63/390,789) and Biosensor and uses thereof (#63/323,968)] derived from this work. O.O.M. is a paid consultant for Broadview Ventures Inc. All other authors declare that they have no competing interests.

Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) hyperactivity causes cardiac arrhythmias, a major source of morbidity and mortality worldwide. Despite proven benefits of CaMKII inhibition in numerous preclinical models of heart disease, translation of CaMKII antagonists into humans has been stymied by low potency, toxicity, and an enduring concern for adverse effects on cognition due to an established role of CaMKII in learning and memory. To address these challenges, we asked whether any clinically approved drugs, developed for other purposes, were potent CaMKII inhibitors. For this, we engineered an improved fluorescent reporter, CaMKAR (CaMKII activity reporter), which features superior sensitivity, kinetics, and tractability for high-throughput screening. Using this tool, we carried out a drug repurposing screen (4475 compounds in clinical use) in human cells expressing constitutively active CaMKII. This yielded five previously unrecognized CaMKII inhibitors with clinically relevant potency: ruxolitinib, baricitinib, silmitasertib, crenolanib, and abemaciclib. We found that ruxolitinib, an orally bioavailable and U.S. Food and Drug Administration–approved medication, inhibited CaMKII in cultured cardiomyocytes and in mice. Ruxolitinib abolished arrhythmogenesis in mouse and patient-derived models of CaMKII-driven arrhythmias. A 10-min pretreatment in vivo was sufficient to prevent catecholaminergic polymorphic ventricular tachycardia, a congenital source of pediatric cardiac arrest, and rescue atrial fibrillation, the most common clinical arrhythmia. At cardioprotective doses, ruxolitinib-treated mice did not show any adverse effects in established cognitive assays. Our results support further clinical investigation of ruxolitinib as a potential treatment for cardiac indications.

---

## INTRODUCTION

Cardiovascular disease is a leading cause of premature death, with more than half a billion patients affected worldwide (1). The multifunctional Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) contributes to physiological regulation of Ca<sup>2+</sup> cycling in cardiomyocytes (CMs) but is unexpectedly dispensable for cardiac function (2-4). In contrast, excessive CaMKII activity is cardiotoxic, and CaMKII inhibition is protective in numerous models of inherited and acquired heart diseases and arrhythmias (5-13). CaMKII hyperactivity is, in part, a consequence of catecholamine stimulation, but clinically approved drugs that inhibit  $\beta$ -adrenergic receptors (“ $\beta$  blockers”) are ineffective at preventing increased CaMKII activity in myocardia obtained from patients with heart failure (14). Thus, developing safe and effective molecules to directly inhibit CaMKII activity is a major unmet need.

Although several inhibitory modalities have been described, none have reached the clinic because of various limitations. KN-62 and KN-93 were the first CaMKII inhibitors (15, 16). These allosteric inhibitors alleviate CaMKII toxicity in animal models (7, 11, 17). Although these compounds remain popular as experimental tools, they were clinically hampered by low potency [median inhibitory concentration (IC<sub>50</sub>) > 2  $\mu$ M], prohibitive off-target toxicities, and failure to inhibit autonomously hyperactive CaMKII (18-20). KN-93 has been recently shown to be a calmodulin inhibitor, which explains its inability to inhibit active CaMKII (21). CaMKII inhibitory peptides (such as CaMKII-IN and autacamtide-2–related inhibitory peptide) have served as powerful genetic tools with impressive affinity and specificity (22, 23) but have failed to translate because of the challenges of peptide

delivery: short plasma half-life, cell impermeability, and suboptimal viral delivery to human myocardium (24). Although peptides can be modified to enhance cell penetrance and have reached clinical trials for other indications, these modifications have not yielded clinically viable CaMKII inhibition. To address these limitations, several adenosine triphosphate (ATP)-competitor small molecules have been identified or developed (25-29). From these, only the natural derivative 3',4'-dihydroxyflavonol (DiOHF) has made it to a human trial (30); this study intended to inhibit CaMKII after ischemia/reperfusion injury but yielded negative results, which were thought to be due to low potency against CaMKII (31). Because CaMKII is important for long-term potentiation and is abundant in excitatory synapses (32), concern for adverse effects on learning and memory has been a major obstacle to developing CaMKII inhibitors (24). We reasoned that discovery of an approved medication, preferably in broad use, with potent CaMKII inhibitory properties would provide critical insights to inform translational researchers, patients, and industry about the viability of CaMKII inhibitors for clinical use.

Development of small-molecule inhibitors could be facilitated by a reporter with high-throughput capability, but existing CaMKII reporters are not suitable for this. A seminal reporter, Camui, suffers from low dynamic range and reports on conformational changes rather than enzymatic activity (33, 34). A more recent reporter, fluorescence resonance energy transfer-based sensor for CaMKII activity (FRESCA), elegantly bypassed this obstacle by sensing CaMKII activity via direct substrate phosphorylation of the reporter (35). This improvement over Camui is limited by FRESCA's dynamic range, which is even lower than that of Camui (~2.7%). On the basis of these limitations, we sought to develop a CaMKII activity reporter that features both high sensitivity and direct kinase sensing, unlike FRESCA or Camui, which have only one of these qualities, thereby making it tractable for in cellulo screening.

In the present study, we address the two major gaps outlined above. First, we engineered a genetically encoded CaMKII activity reporter for live cell screening featuring the highest sensitivity and kinetics reported for a CaMKII reporter. Then, we screened 4475 compounds that have reached human trials and/or U.S. Food and Drug Administration (FDA) approval and identified several compounds capable of inhibiting hyperactive CaMKII. From these, ruxolitinib displayed outstanding repurposing characteristics, including high potency at relevant concentrations, low toxicity, and known low brain penetrance. Ruxolitinib prevented inherited and acquired arrhythmias arising from CaMKII hyperactivity, including catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fibrillation (AF), in validated murine disease models without impairing cognitive function.

## RESULTS

### Development of a CaMKII reporter suitable for high-throughput screening

The discovery of circularly permuted green fluorescent protein (cpGFP) has led to numerous reporters that detect ions, metabolites, and enzyme activity by coupling reconstitution of GFP fluorescence with the process of interest (36-38). Using kinase-sensing cpGFP (38), we engineered a new CaMKII activity reporter. Screening among known CaMKII substrates, the CaMKII autophosphorylation peptide MHRQETVDCLK (autoregulatory

domain sequence shared by CaMKII $\alpha/\delta$ ) fused to the 5' end of kinase-sensing cpGFP led to the highest CaMKII-dependent response (fig. S1A). We refer to this reporter as CaMKAR (CaMKII activity reporter), composed of the substrate peptide, cpGFP, and a phosphorylated amino acid binding domain. Upon phosphorylation of the substrate by CaMKII, the phosphoresidue binding domain causes an intramolecular conformational change that restores GFP fluorescence (Fig. 1A). Similar to previous reporters, this reconstitution is excitation ratiometric: GFP emission (~520-nm light) excited by ~488-nm light increases, whereas GFP emission excited by ~405 nm is unchanged or decreases (37, 38). We therefore express CaMKAR signal as the ratio ( $R$ ) of these two channels (Fig. 1A). To test CaMKAR dynamics, we treated CaMKAR-expressing human embryonic kidney (HEK) 293T cells with ionomycin, causing intracellular Ca<sup>2+</sup> influx and activation of endogenous CaMKII (Fig. 1, B and C). This resulted in a rapid increase in  $R$  relative to baseline ( $R/R_0$ ). Stimulation with ionomycin in HEK293T cells expressing constitutively active (CA) CaMKII revealed an in cellulo maximal dynamic range of 3.27-fold or  $227 \pm 11.1\%$  (fig. S1B). Because the 405-nm channel is largely unchanged upon stimulation, CaMKAR can also be used intensimetrically by only quantifying the 488-nm channel intensity; this modality retains  $96.4 \pm 1.6\%$  of the dynamic range compared with ratiometric mode (fig. S1C). Pretreatment with the ATP-competitive CaMKII inhibitor AS100397 (fig. S1, D and E), a congener of AS105 (25, 39, 40), eliminates CaMKAR signal, and posttreatment with the Ca<sup>2+</sup>-chelator EGTA rapidly reduces CaMKAR signal (Fig. 1C). We validated that CaMKAR senses bona fide CaMKII-catalyzed phosphorylation by orthogonal approaches. First, we cotransfected CaMKAR with constructs that express CaMKII $\delta$  variants under a doxycycline-inducible promoter in HEK293T cells: As expected, overexpression of wild-type (WT) CaMKII without Ca<sup>2+</sup> stimulation led to no change in CaMKAR signal, and expression of CA CaMKII<sup>T287D</sup>, but not kinase-defective CaMKII<sup>K43M</sup>, increases CaMKAR signal (Fig. 1D), suggesting that kinase activity is a requirement for CaMKAR signal induction. To ensure that sensing occurs via phosphorylation at the proposed substrate site (threonine-6), we repeated the previous experiment using CaMKAR containing a nonphosphorylatable alanine residue at position 6 (T6A mutation); this mutation completely abolished sensing to both ionomycin stimulation and CA CaMKII<sup>T287D</sup> (Fig. 1E). Further supporting a phosphorylation-dependent mechanism, ionomycin-stimulated CaMKAR signal was enhanced and failed to resolve when coincubated with the pan-phosphatase inhibitor calyculin A (fig. S1F). Together, these assays support that CaMKAR senses CaMKII activity by direct phosphorylation of threonine-6 and that the CaMKAR signal is reversible via phosphatases. CaMKAR is sensitive to the CA constructs for all four human CaMKII isoforms ( $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$ ) and the three prevalent splice variants of CaMKII $\delta$  ( $\delta$ C,  $\delta$ B, and  $\delta$ 9) (fig. S1, G and H).

Next, we sought to benchmark CaMKAR's performance and specificity. Camui was the first CaMKII reporter developed and is still widely used (33, 34). However, it has important limitations: Camui contains and overexpresses brain isoform CaMKII $\alpha$  and has relatively low dynamic range (~5 to 70% versus CaMKAR's  $227 \pm 11.1\%$ ), and it reports conformational change rather than enzymatic activity (table S1) (34, 41). In HEK293T cells, CaMKAR displays a nearly 10-fold greater signal-to-noise ratio (fig. S2A) and is about threefold faster ( $\tau_{\text{CaMKAR}} = 7.4$  versus  $\tau_{\text{Camui}} = 21.6$ ; fig. S2B). In cultured rat hippocampal

neurons, Camui failed to detect catalytic inhibition of CaMKII, whereas CaMKAR detected both catalytic and allosteric inhibition (fig. S2, C to G). Head-to-head comparison of these reporters in these cells demonstrated that CaMKAR is more sensitive than Camui and another reporter, FRESCA, under the same stimulus (fig. S2, H and I). Thus, CaMKAR appears to have both improved sensitivity and kinetics. Because  $\text{Ca}^{2+}$ -mobilizing agents can activate many kinases, we set to validate CaMKAR's specificity. In rat CMs (which highly express endogenous CaMKII $\delta$ ), pacing-induced CaMKII activity as detected by CaMKAR was abrogated by a 3-day incubation with anti-CaMKII $\delta$  small interfering RNA (fig. S2J). In HEK293T cells, CaMKAR is insensitive to coexpression with CA CaMKI and CaMKIV (Fig. 1F). CaMKAR also failed to sense forskolin/IBMX-mediated cyclic adenosine monophosphate-dependent protein kinase (PKA) activation, phorbol 12-myristate 13-acetate (PMA)-mediated protein kinase C (PKC) activation, and phorbol 12,13-dibutyrate (PDBu)-mediated PKD activation (Fig. 1, G to I). We verified that the concentrations of forskolin/IBMX and PMA used in these studies were sufficient to elicit PKA (fig. S2K) and PKC activity (fig. S2L). Similarly, CaMKAR's response to ionomycin was unhindered by Gö6976, a dual PKC/PKD inhibitor (fig. S2M).

We leveraged the unique properties of CaMKAR to measure CaMKII activity *in vitro*. Recombinant CaMKAR is fully functional and exhibits appropriate spectral changes upon incubation with purified CaMKII (fig. S3A). These changes are ATP dependent, further confirming a dependence on phosphorylation for reporter function (fig. S3, A to C). CaMKAR displays a larger dynamic range *in vitro* ( $264 \pm 2.1\%$ ) compared with cell-based assays ( $227 \pm 11.1\%$ ), and the rate of the reaction is determined by the amount of CaMKII (fig. S3, D and E). Together, we have demonstrated that CaMKAR is a bona fide CaMKII activity reporter with unprecedented sensitivity, fast kinetics, specificity, and suitability for live-cell and *in vitro* drug screening.

### CaMKAR-based screen of drugs in clinical use

Next, we aimed to canvass the clinically approved pharmacopeia for drugs that are potent CaMKII inhibitors. For high-throughput screening, we first created a stable line of human K562 cells that coexpress CaMKAR and CaMKII $\delta^{\text{CA}}$ : K562<sup>CaMKII-CaMKAR</sup> (Fig. 2A). We chose K562 cells because they grow at high density and remain viable after expression of active CaMKII (fig. S4A). The use of CA CaMKII instead of  $\text{Ca}^{2+}$ /calmodulin-activated CaMKII increases the likelihood of identifying catalytic inhibitors rather than calmodulin inhibitors (such as KN-93). The sensitivity of CaMKAR enables screening to occur in small culture volumes: CaMKII inhibition by AS100397 is detectable in as little as 30  $\mu\text{l}$  of cell culture (fig. S4B). As our primary screen, we tested this cell line against the Johns Hopkins Drug Library v3.0, constructed by pooling 4475 compounds approved for human use by regulatory agencies from the United States, Europe, Japan, and China. This library targets 44 different pathway families and contains more than 100 kinase inhibitors (data file S1). After 12 hours of treatment, cells were assayed for CaMKAR signal using high-content imaging. Among drugs with an inhibitory signal, we found 118 compounds that reduced CaMKII activity by 60% or more, using a false discovery-adjusted *P* value cutoff of  $<3 \times 10^{-5}$  (Fig. 2B and data file S1). We reasoned that these hits likely contained a mixture of genuine inhibitors and false positives (such as autofluorescent compounds, indirect inhibitors, and

phosphatase activators). To discern true inhibitors from false positives, we performed a secondary screen using our recombinant CaMKAR in vitro assay as described in fig. S3. In this assay, we measured fluorescence in a mixture of CaMKII, Ca<sup>2+</sup>-bound calmodulin (Ca<sup>2+</sup>/CaM), and CaMKAR at baseline, after drug addition and after catalysis was initiated with ATP. Thus, this screen could help determine whether a drug was autofluorescent and/or a direct inhibitor. Our assay revealed 13 compounds with meaningful inhibition of CaMKII activity (Fig. 2C and data file S2). Both screening steps returned our positive control, pan-kinase inhibitor staurosporine. To remove weak inhibitors and further validate our results, these compounds were tested with HEK293T cells coexpressing CaMKAR and CaMKIIT287D in our laboratory (fig. S5) and in vitro by an independent commercial laboratory (data file S2). These combined results identified five potent CaMKII inhibitors—ruxolitinib, crenolanib, baricitinib, abemaciclib, and silmitasertib—which are all known to be ATP-competitive kinase inhibitors (Figs. 2D and fig. S6). None of the compounds were designed against kinases in the CAMK superfamily, and three of the five compounds are intended against tyrosine kinases, one of the most dissimilar kinase families to CAMK by kinase domain homology (Fig 2D). Unlike KN-93 (23), all five compounds inhibited Ca<sup>2+</sup>-independent, autonomously hyperactive CaMKII in HEK293T cells (Fig. 2E, left). In this assay, crenolanib, ruxolitinib, abemaciclib, and baricitinib were more potent than AS100397, and all drugs except crenolanib were less cytotoxic after a 12-hour exposure (Fig. 2E, right). Thus, ruxolitinib, abemaciclib, and baricitinib appeared to be more potent and less toxic than our tool compound in cultured cells.

### Clinically approved drugs inhibit CaMKII in cardiac cells

Because of the established benefits of CaMKII inhibition in cardiovascular disease models, we asked whether these five compounds could inhibit CaMKII in CMs. In neonatal rat ventricular myocytes (NRVMs), we can stimulate CaMKII activity by rapid field pacing (Fig. 3, A and B). Preincubation of all five compounds inhibited this response at high doses (Fig. 3C). However, to determine which compounds are likely to have an effect at clinically achievable doses, we adjusted each concentration to their respective maximal human plasma concentrations (42-46). This revealed that ruxolitinib, crenolanib, abemaciclib, and silmitasertib, but not baricitinib, sustained inhibition (Fig. 3, D and E). Because of its high potency and low toxicity and favorable safety profile among our hits (table S2), we henceforth focused on ruxolitinib. We then ascertained that ruxolitinib is capable of inhibiting preactivated CaMKII, returning activity to baseline within 30 s in CMs that began pacing before drug administration (Fig. 3F). Head-to-head comparison shows that ruxolitinib is more than 10-fold more potent than DiOHF (Fig. 3G) (29, 30). This inhibitory effect appears to be independent of ruxolitinib's Janus kinase 1/2 (JAK1/2) inhibition. For one, we found multiple JAK1/2 inhibitors in our screen that failed to reduce the CaMKAR signal (fig. S7A). Among these compounds, their known IC<sub>50</sub> values against JAK1/2 did not significantly correlate ( $P = 0.85$  for JAK1 and  $P = 0.11$  for JAK2) with CaMKAR signal inhibition in our screen (fig. S7B). Filgotinib, another FDA-approved drug with similar potency against JAK1/2, failed to inhibit pacing-induced CaMKII activity (fig. S7C). Last, an in vitro biochemical assay with recombinant CaMKII protein confirmed inhibition of CaMKII with ruxolitinib in the absence of JAK1/2 with an inhibitory constant ( $K_i$ ) of  $23.4 \pm 2.18$  nM (compared with DiOHF, which has a published IC<sub>50</sub> of 250 nM) and an



ATP-competitive mechanism (fig. S7D). Forty-eight-hour exposure in NRVMs revealed that ruxolitinib is well tolerated up to 100  $\mu$ M, which was similar to DiOHF and superior to KN-93 and AS100397 (Fig. 3H). We conclude that the drugs identified in our screen can inhibit CaMKII in cardiac cells, but among these, ruxolitinib appears to be best suited for repurposing because of its potency and low toxicity.

We then evaluated whether ruxolitinib could also inhibit CaMKII activity in vivo. Ten-minute systemic pretreatment with ruxolitinib at 41, 75, and 180 mg/kg suppressed isoproterenol-induced phosphorylation of phospholamban at threonine-17, a validated marker of CaMKII activity (47-49), in a concentration-dependent manner (Fig. 4, A to C). This dosing range was chosen because doses at 30 to 180 mg/kg have been used for JAK inhibition in mice (50-54), and doses at 60 to 90 mg/kg have been reported to be analogous to the prescribed 20 to 25 mg in humans (see Discussion for limitations) (51-53). Together, our data demonstrate that ruxolitinib can inhibit CaMKII in CMs and functions rapidly in vivo.

### Ruxolitinib inhibits arrhythmias in mouse and patient-derived models

Given its robust inhibition of CaMKII in cellulo and in vivo, we tested whether ruxolitinib can ameliorate CaMKII-associated cardiac pathology. We first examined CPVT because CaMKII hyperactivity plays an essential role in this arrhythmia (10, 11, 13, 55). We isolated peripheral blood mononuclear cells from a patient with recurrent exercise-induced arrhythmia and a dominant mutation in the ryanodine receptor type 2 (*RYR2*<sup>S404R/WT</sup>) for re-programming into induced pluripotent stem cells (iPSCs) (15). After differentiation into functional CMs (iPSC-CMs), we performed steady-rate electrical pacing at 1 Hz for 10 s, followed by cessation of pacing during continuous Ca<sup>2+</sup> imaging. The frequency of spontaneous abnormal Ca<sup>2+</sup> release events (aCREs) after the cessation of pacing reflects the cellular mechanism for CPVT and is markedly increased in iPSC-CMs with pathogenic CPVT mutations (Fig. 5A). Preincubation with ruxolitinib effectively suppressed aCREs in *RYR2*<sup>S404R/WT</sup> iPSC-CMs compared with vehicle only (Fig. 5B). Automated analysis of Ca<sup>2+</sup> transients during steady-rate pacing did not reveal any effects on peak Ca<sup>2+</sup> amplitude (Fig. 5C), transient duration (Fig. 5D), or upstroke velocity (Fig. 5E). In addition, ruxolitinib treatment normalized the downstroke velocity of paced Ca<sup>2+</sup> transients *RYR2*<sup>S404R/WT</sup> iPSC-CMs to WT values (Fig. 5F). We also investigated the effects of the other drugs identified by our screen to test whether any were superior to ruxolitinib in reversing this disease phenotype. Among these, ruxolitinib was the best at suppressing aCREs in *RYR2*<sup>S404R/WT</sup> iPSC-CMs (fig. S8A) and restoring Ca<sup>2+</sup> transient parameters (fig. S8, B to E).

Arrhythmias are emergent properties of tissues and not just single cells. Thus, we next focused on a validated mouse model of CPVT. Mice with the knock-in mutation *Ryr2*<sup>R176Q</sup> have spontaneous and inducible ventricular arrhythmias in response to adrenergic stimulation and ventricular pacing (56). To first test that ruxolitinib could suppress the single-cell arrhythmogenic phenotype in the *Ryr2*<sup>R176Q/WT</sup> genotype, we isolated adult CMs from WT and mutant mice. Similar to iPSC-CMs derived from a patient suffering from CPVT, *Ryr2*<sup>R176Q/WT</sup> adult CMs demonstrated aCREs after the cessation of steady-rate





cardiac inhibition can be achieved without impairing cognition. To test whether this was the case in our models, we treated mice with ruxolitinib and subjected them to the novel object recognition test (NORT) and the Y maze spatial memory test (Fig. 8A), two established behavioral paradigms that test spatial short-term memory. These were chosen because CaMKII inhibition is known to affect both short-term and spatial memory (68-70), and numerous studies observe robust deficits in novel object recognition upon CaMKII inhibition (68, 71-74). Neither single dose (1 hour before) nor multiple doses (twice daily for 7 days) of ruxolitinib (75 or 41 mg/kg) caused significant differences in novel object recognition ( $P = 0.56$  and  $P = 0.68$ ), as measured by percentage of time spent with the novel object (Fig. 8, B and C). Total distance traveled during testing was similar for both groups, confirming equivalent locomotion (Fig. 8, D and E). In the Y maze test, single dosing using the lower dose showed decreased preference for the novel arm (Fig. 8F), but this effect was not seen in the higher dose or in either of the multiple dosing cohorts (Fig. 8, F and G).

To assess longer-term spatial memory formation, we tested the effect of ruxolitinib treatment on Barnes maze performance, a test that is also validated to detect CaMKII disruption (69). Mice were initiated on ruxolitinib (150 mg/kg per day) 1 day before training and were maintained on treatment throughout the entire study to ensure continuous exposure to drug (fig. S12A). At the study end point, there was no difference in maze-solving latency between the treatment or vehicle groups (fig. S12B). During the training trials, there was no significant effect in latency ( $P = 0.57$ ), primary errors ( $P = 0.34$ ), and total errors ( $P = 0.42$ ) due to ruxolitinib treatment; reassuringly, all three parameters were significantly decreased across days ( $P < 0.0001$ ,  $P = 0.0037$ , and  $P < 0.0001$ ), demonstrating adequate learning (fig. S12, C to E). These results suggest that, at tested doses, ruxolitinib did not lead to detectable impairment of short-term or spatial memory, demonstrating that it may be possible to limit cardiac CaMKII activity without substantial memory impairment in mice.

## DISCUSSION

In this work, we developed and validated CaMKAR, a fluorescent CaMKII activity reporter uniquely suited for high-throughput screening. CaMKAR displays the highest dynamic range of all CaMKII reporters to date; a high degree of specificity; and versatility afforded by ratiometric, intensimetric, and in vitro functionality. We demonstrated these properties by screening a collection of clinically approved compounds as possible CaMKII inhibitors. Our data revealed that CaMKII inhibitors already exist in the human pharmacopeia and that FDA-approved ruxolitinib may be a candidate for cardiovascular repurposing.

This work has several limitations. First, it remains to be determined whether ruxolitinib will have an effect on CaMKII in humans at safely tolerated doses. Although our in vitro and in cellulo data support that achievable concentrations will have an effect, our in vivo data are based on several assumptions. Dosing at 60 to 90 mg/kg has been previously reported to be analogous to human 20- to 25-mg doses (51-53), but these studies lack definitive pharmacological data to demonstrate this equivalency. The widely used Nair and Jacob scale (75) estimates that the mouse equivalent of 25 mg is ~5 mg/kg, a dose that is too low for an effect in our hands. However, the maximally tolerated human dose of 200 mg (42, 76) yields a mouse dose of ~40 mg/kg, which is within an order of magnitude of our

in vivo dosing. Nevertheless, the Nair and Jacob method is a “rule-of-thumb” approach, and it highlights that efficacy in humans will require empirical determination in clinical studies. In addition, chronicity and duration of effect might vary in humans based on route of administration and differences in drug metabolism across species. Although our study used systemic intraperitoneal delivery, ruxolitinib is currently administered orally, with >95% availability (77). In our system, we only evaluated short-term inhibition of CaMKII (10 to 25 min after delivery), and the duration of inhibition remains to be determined. Last, our behavioral results support a lack of neurocognitive effects at cardioprotective doses, but these assays do not exclude effects in the immediate term (which includes the window of activity confirmed in this study) or after chronic therapy. Despite its poor blood-brain barrier penetrance (66), ruxolitinib has been reported to modulate astroglial inflammation in mouse brains (78). Therefore, although no memory deficits have been reported in patients, focused clinical studies will be necessary to determine whether subtle neurocognitive effects occur.

To demonstrate translational potential, we focused on CPVT and AF, two diseases driven by CaMKII hyperactivity (13, 55-59, 79-81). In both patient-derived human CMs and in mice, ruxolitinib displayed near-complete prevention of arrhythmic phenotypes and a normalization of Ca<sup>2+</sup> handling. We are hopeful that the therapeutic potential shown here can rapidly translate into patients for two main reasons. First, CPVT murine knock-in models harboring human disease mutations in RyR2 closely recapitulate human responses to stress (56). Second, the CaMKII-RyR2-dependent mechanism in CPVT and AF is also shared by numerous arrhythmogenic conditions, including inherited (Timothy syndrome, Duchenne’s muscular dystrophy, and ankyrin B mutations) and acquired (such as glycoside toxicity, heart failure, and alcoholic cardiomyopathy) diseases (5).

Although animal studies have repeatedly demonstrated that CaMKII blockade is cardioprotective, pharmaceutical companies have remained cautious about developing CaMKII inhibitors because of its pivotal role in memory (65). Our results suggest that several drugs already in circulation, taken by thousands to millions of patients, can inhibit CaMKII. Our findings, particularly in regard to ruxolitinib, support a reinvigoration of CaMKII inhibitor development and demonstrate that cardiac CaMKII blockade without impairing cognition may be possible with small molecules.

FDA-approved screens hold exciting potential for drug repurposing; nevertheless, FDA approval for an original indication does not guarantee approval for other indications. Thus, excitement for repurposing must be tempered with careful evaluation of ruxolitinib’s side effect profile, particularly because our biochemical data suggest that CaMKII and JAK1/2 inhibition will be concomitant. Systemic ruxolitinib is used to treat polycythemia vera, myelofibrosis, and splenomegaly. Because of JAK1/2 inhibition, prolonged treatment can result in herpes zoster infection and reversible anemia and thrombocytopenia (82, 83). Encouragingly, two large-scale cohorts of patients taking long-term ruxolitinib (median exposures of 12.4 and of 34.4 months) determined that few patients discontinue treatment because of anemia (<2.6%) or thrombocytopenia (<3.6%) (82, 83). Concern for adverse effects can be abrogated by limiting exposure length, and in agreement with this, ruxolitinib is well tolerated at up to 200 mg in healthy volunteers in single or short-term dosing (42, 84). Thus, we predict that repurposing will be most readily applicable for indications that

require short treatment courses because these likely offer the optimal trade-off between CaMKII inhibition and mitigation of undesirable JAK1/2 effects. We have identified three unmet clinical scenarios that match these criteria. One is postoperative AF, which affects 20 to 40% of cardiac surgery patients and is independently associated with increased mortality, length of stay, and health care cost (85). A majority of cases happen within 3 days, and >90% happen by day 6 after surgery (85, 86). Another indication could be postmyocardial infarction ventricular tachycardia, a considerable source of peri-infarct mortality, which also occurs predominantly (90%) within the first 48 hours (87). A final setting would be cardiac electrical storm, whereby patients experience multiple episodes of ventricular tachycardia and fibrillation within 24 to 48 hours. All three conditions are exacerbated by CaMKII (88-90), feature  $\beta$ -adrenergic blockade as a mainstay therapy, which has been shown to be insufficient to block CaMKII in human biopsies (14), and occur within short and predictable time frames where a short course of ruxolitinib would be feasible. Other experimental CaMKII-modifying modalities, such as antisense oligonucleotides and inhibitor-encoding gene therapy, take effect in the order of days to weeks, which lessens their utility in these acute indications. We demonstrated that ruxolitinib can inhibit preactivated CaMKII and rescue ongoing arrhythmia, which supports a therapeutic role for ruxolitinib as a “pill-in-the-pocket” for AF.

Despite its impressive mechanistic response to CaMKII inhibition in animal models, there are no current CaMKII-inhibiting or disease-specific therapies available for CPVT. Although the recent addition of flecainide therapy has ameliorated arrhythmic events in many patients, a substantial fraction are refractory to flecainide therapy, experience breakthrough events, and die from sudden arrhythmia despite maximal medical therapy and use of implantable cardiac defibrillators (ICDs). The use of ICDs is associated with potentially lethal ICD storms and death in some patients with exhausted therapies (91). Therefore, although CPVT would require chronic administration, patients resistant to all other therapies may find benefits that outweigh ruxolitinib’s on-target effects.

CaMKAR’s high sensitivity and fast kinetics will enable elucidation of pathologic CaMKII activity dynamics with high spatiotemporal resolution. Furthermore, CaMKAR can be scaled in cell culture, which will permit more ambitious chemical screens. The molecules identified here can also serve as scaffolds for medicinal chemistry to amplify their CaMKII potency and minimize their originally intended effects. Given the lengthy regulatory approval process for novel compounds, it may be worth exploring potential cardiac indications for ruxolitinib itself. Last, although CaMKII is known to drive an extensive number of cardiac pathologies, it has been shown to underpin other illnesses, including asthma and cancer (5). Future study will be needed to determine the utility of our identified compounds in these diseases.

## MATERIALS AND METHODS

### Study design

The goal of this study was to engineer a CaMKII reporter suitable for high-throughput screening and identify drugs that can be repurposed as CaMKII inhibitors for cardiac indications. All animal studies were approved by appropriate animal care and use

committees. Mice of both sexes were used unless noted in the methods. Animal number was determined by prior experience and published reports. Mice were randomly assigned to treatment conditions, and when an experiment spanned across multiple days, all conditions were represented in each cohort. Behavioral tests were performed by an independent experimenter blinded to the conditions. Experiments determining protection of ruxolitinib in CPVT models (cells and mice) were performed by experimenters blinded to the identity of the compound. Imaging data analysis was done in a computer-automated fashion to avoid human bias.

### Statistics

Imaging summary data were condensed and organized with R Studio. Statistical testing was done with GraphPad Prism v8.2.0 as described in each figure. Normality was tested via Shapiro-Wilk with 0.05 alpha level. Signal-to-noise ratio was calculated as described (37): single-cell maximal ratio change after stimulation divided by the SD across four baseline time points.

### Data and materials availability:

All data associated with this study are present in the paper or the Supplementary Materials. CREM-Ib C-X-overexpressing mice are available from X.H.T.W. and F.U.M. through a material transfer agreement with the University of Münster. Raw image files, CaMKAR plasmids, and the AS100397 compound are available through a material transfer agreement upon request (contact E.D.L. at [betsy.luczak@jhmi.edu](mailto:betsy.luczak@jhmi.edu)).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments:

We are thankful to the Johns Hopkins Biostatistics, Epidemiology, and Data Management (BEAD) Core for statistical analysis stewardship, Fondation Leducq for providing the AS100397 compound, D. A. Kass and F. Wu for providing NRVMs, and J. Yang for animal maintenance.

### Funding:

These studies were supported by the American Heart Association Predoctoral Fellowship 905878 (to O.E.R.G.); NIH grants R35HL140034 (to M.E.A.), K08HL140197 (to V.J.B.), K12HL141952 (to O.O.M.), UG3TR003279-02 (to D.W.), R01HL089598, R01HL147108, R01HL153350, R01HL160992 (to X.H.T.W.), RF1MH126707 (to R.L.H.), and K99HL155840 (to B.L.L.); the Sarnoff Fellowship (to L.J.N.); the Translational Research Program at Boston Children's Hospital (to N.P.); the RWJF/AHA Harold Amos Faculty Development Program Grant 967117 (to O.O.M.); and the Flight Attendant Medical Research Institute (to J.O.L.).

## REFERENCES AND NOTES

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N,

- Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group, Global burden of cardiovascular diseases and risk factors, 1990–2019: Update From the GBD 2019 Study. *J. Am. Coll. Cardiol* 76, 2982–3021 (2020). [PubMed: 33309175]
2. Wu Y, Gao Z, Chen B, Koval OM, Singh MV, Guan X, Hund TJ, Kutschke W, Sarma S, Grumbach IM, Wehrens XHT, Mohler PJ, Song L-S, Anderson ME, Calmodulin kinase II is required for fight or flight sinoatrial node physiology. *Proc. Natl. Acad. Sci. U.S.A* 106, 5972–5977 (2009). [PubMed: 19276108]
  3. Kreusser MM, Lehmann LH, Keranov S, Hoting M-O, Oehl U, Kohlhaas M, Reil J-C, Neumann K, Schneider MD, Hill JA, Dobrev D, Maack C, Maier LS, Gröne H-J, Katus HA, Olson EN, Backs J, Cardiac CaM kinase II genes  $\delta$  and  $\gamma$  contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. *Circulation* 130, 1262–1273 (2014). [PubMed: 25124496]
  4. Beckendorf J, van den Hoogenhof MMG, Backs J, Physiological and unappreciated roles of CaMKII in the heart. *Basic Res. Cardiol* 113, 29 (2018). [PubMed: 29905892]
  5. Reyes Gaído OE, Nkashama LJ, Schole KL, Wang Q, Umapathi P, Mesubi OO, Konstantinidis K, Luczak ED, Anderson ME, CaMKII as a therapeutic target in cardiovascular disease. *Annu. Rev. Pharmacol. Toxicol* 63, 249–272 (2023). [PubMed: 35973713]
  6. Joiner MLA, Koval OM, Li J, Julie He B, Allamargot C, Gao Z, Luczak ED, Hall DD, Fink BD, Chen B, Yang J, Moore SA, Scholz TD, Strack S, Mohler PJ, Sivitz WI, Song LS, Anderson ME, CaMKII determines mitochondrial stress responses in heart. *Nature* 491, 269–273 (2012). [PubMed: 23051746]
  7. Zhang R, Khoo MSC, Wu Y, Yang Y, Grueter CE, Ni G, Price EE, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME, Calmodulin kinase II inhibition protects against structural heart disease. *Nat. Med* 11, 409–417 (2005). [PubMed: 15793582]
  8. Grueter CE, Colbran RJ, Anderson ME, CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. *J. Mol. Med* 85, 5–14 (2007). [PubMed: 17119905]
  9. He BJ, Joiner MLA, Singh MV, Luczak ED, Swaminathan PD, Koval OM, Kutschke W, Allamargot C, Yang J, Guan X, Zimmerman K, Grumbach IM, Weiss RM, Spitz DR, Sigmund CD, Blankesteyn WM, Heymans S, Mohler PJ, Anderson ME, Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. *Nat. Med* 17, 1610–1618 (2011). [PubMed: 22081025]
  10. Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M, Nakahama H, Portararo P, Bloise R, Napolitano C, Condorelli G, Priori SG, CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. *Cell Death Dis.* 4, e843 (2013). [PubMed: 24113177]
  11. Konstantinidis K, Bezzerides VJ, Lai L, Isbell HM, Wei AC, Wu Y, Viswanathan MC, Blum ID, Granger JM, Heims-Waldron D, Zhang D, Luczak ED, Murphy KR, Lu F, Gratz DH, Manta B, Wang Q, Wang Q, Kolodkin AL, Gladyshev VN, Hund TJ, Pu WT, Wu MN, Cammarato A, Bianchet MA, Shea MA, Levine RL, Anderson ME, MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. *J. Clin. Invest* 130, 4663–4678 (2020). [PubMed: 32749237]
  12. Wu Y, Wang Q, Feng N, Granger JM, Anderson ME, Myocardial death and dysfunction after ischemia-reperfusion injury require CaMKII $\delta$  oxidation. *Sci. Rep* 9, 9291 (2019). [PubMed: 31243295]
  13. Bezzerides VJ, Caballero A, Wang S, Ai Y, Hyland RJ, Lu F, Heims-Waldron DA, Chambers D, Zhang D, Abrams DJ, Pu WT, Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca<sup>2+</sup>/calmodulin-dependent kinase II. *Circulation* 140, 405–419 (2019). [PubMed: 31155924]
  14. Dewenter M, Neef S, Vettel C, Lämmle S, Beushausen C, Zelarayan LC, Katz S, von der Lieth A, Meyer-Roxlau S, Weber S, Wieland T, Sossalla S, Backs J, Brown JH, Maier LS, El-Armouche A, Calcium/calmodulin-dependent protein kinase II activity persists during chronic  $\beta$ -adrenoceptor



- blockade in experimental and human heart failure. *Circ. Heart Fail* 10, e003840 (2017). [PubMed: 28487342]
15. Tokumitsu H, Chijiwa T, Hagiwara M, Mizutani A, Terasawa M, Hidaka H, KN-62, 1-[*N,O*-bis(5-isoquinolinesulfonyl)-*N*-methyl-L-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *J. Biol. Chem* 265, 4315–4320 (1990). [PubMed: 2155222]
  16. Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H, The newly synthesized selective Ca<sup>2+</sup>/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. *Biochem. Biophys. Res. Commun* 181, 968–975 (1991). [PubMed: 1662507]
  17. Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky E, Hajjar RJ, Kranias EG, Mundiña-Weilenmann C, Mattiazzi A, CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia–reperfusion injury. *Cardiovasc. Res* 73, 689–698 (2007). [PubMed: 17217936]
  18. Ledoux J, Chartier D, Leblanc N, Inhibitors of calmodulin-dependent protein kinase are nonspecific blockers of voltage-dependent K<sup>+</sup> channels in vascular myocytes. *J. Pharmacol. Exp. Ther* 290, 1165–1174 (1999). [PubMed: 10454491]
  19. Rezazadeh S, Claydon TW, Fedida D, KN-93 (2-[*N*-(2-hydroxyethyl)]-*N*-(4-methoxybenzenesulfonyl)amino-*N*-(4-chlorocinnamyl)-*N*-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. *J. Pharmacol. Exp. Ther* 317, 292–299 (2006). [PubMed: 16368898]
  20. Hegyi B, Chen-Izu Y, Jian Z, Shimkunas R, Izu LT, Banyasz T, KN-93 inhibits IKr in mammalian cardiomyocytes. *J. Mol. Cell. Cardiol* 89, 173–176 (2015). [PubMed: 26463508]
  21. Wong MH, Samal AB, Lee M, Vlach J, Novikov N, Niedziela-Majka A, Feng JY, Koltun DO, Brendza KM, Kwon HJ, Schultz BE, Sakowicz R, Saad JS, Papalia GA, The KN-93 molecule inhibits calcium/calmodulin-dependent protein kinase II (CaMKII) activity by binding to Ca<sup>2+</sup>/CaM. *J. Mol. Biol* 431, 1440–1459 (2019). [PubMed: 30753871]
  22. Chang BH, Mukherji S, Soderling TR, Characterization of a calmodulin kinase II inhibitor protein in brain. *Proc. Natl. Acad. Sci. U.S.A* 95, 10890–10895 (1998). [PubMed: 9724800]
  23. Vest RS, Davies KD, O’Leary H, Port JD, Bayer KU, Dual mechanism of a natural CaMKII inhibitor. *Mol. Biol. Cell* 18, 5024–5033 (2007). [PubMed: 17942605]
  24. Pellicena P, Schulman H, CaMKII inhibitors: From research tools to therapeutic agents. *Front. Pharmacol* 140, 405–419 (2014).
  25. Neef S, Steffens A, Pellicena P, Muströph J, Lebek S, Ort KR, Schulman H, Maier LS, Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor. *J. Mol. Cell. Cardiol* 115, 73–81 (2018). [PubMed: 29294328]
  26. Lebek S, Plöbl A, Baier M, Muströph J, Tarnowski D, Lucht CM, Schopka S, Flörchinger B, Schmid C, Zausig Y, Pagratis N, Marchand B, Koltun DO, Hung WK, Ahmadyar S, Belardinelli L, Maier LS, Wagner S, The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity. *J. Mol. Cell. Cardiol* 118, 159–168 (2018). [PubMed: 29614261]
  27. Beauverger P, Ozoux M-L, Bégis G, Glénat V, Briand V, Philippo M-C, Daveu C, Tavares G, Roy S, Corbier A, Briand P, Dorchies O, Bauchet A-L, Nicolai E, Duclos O, Tamarelle D, Pruniaux M-P, Muslin AJ, Janiak P, Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy. *Cardiovasc. Res* 116, 329–338 (2020). [PubMed: 31038167]
  28. Zhang J, Liang R, Wang K, Zhang W, Zhang M, Jin L, Xie P, Zheng W, Shang H, Hu Q, Li J, Chen G, Wu F, Lan F, Wang L, Wang S-Q, Li Y, Zhang Y, Liu J, Lv F, Hu X, Xiao R-P, Lei X, Zhang Y, Novel CaMKII- $\delta$  inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. *Circulation* 145, 1154–1168 (2022). [PubMed: 35317609]
  29. Lim NR, Thomas CJ, Silva LS, Yeap YY, Yap S, Bell JR, Delbridge LMD, Bogoyevitch MA, Woodman OL, Williams SJ, May CN, Ng DCH, Cardioprotective 3’,4’-dihydroxyflavonol attenuation of JNK and p38MAPK signalling involves CaMKII inhibition. *Biochem. J* 456, 149–161 (2013). [PubMed: 24032640]

30. Boyle AJ, Schultz C, Selvanayagam JB, Moir S, Kovacs R, Dib N, Zlotnick D, Al-Omary M, Sugito S, Selvarajah A, Collins N, McLachlan G, Calcium/calmodulin-dependent protein kinase II delta inhibition and ventricular remodeling after myocardial infarction. *JAMA Cardiol.* 6, 762–768 (2021). [PubMed: 33851966]
31. Anderson ME, To be or not to be a CaMKII inhibitor? *JAMA Cardiol.* 6, 769–770 (2021). [PubMed: 33851950]
32. Lisman J, Yasuda R, Raghavachari S, Mechanisms of CaMKII action in long-term potentiation. *Nat. Rev. Neurosci* 13, 169–182 (2012). [PubMed: 22334212]
33. Takao K, Okamoto K-I, Nakagawa T, Neve RL, Nagai T, Miyawaki A, Hashikawa T, Kobayashi S, Hayashi Y, Visualization of synaptic Ca<sup>2+</sup>/calmodulin-dependent protein kinase II activity in living neurons. *J. Neurosci* 25, 3107–3112 (2005). [PubMed: 15788767]
34. Erickson JR, Patel R, Ferguson A, Bossuyt J, Bers DM, Fluorescence resonance energy transfer-based sensor Camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes. *Circ. Res* 109, 729–738 (2011). [PubMed: 21835909]
35. Ardestani G, West MC, Maresca TJ, Fissore RA, Stratton MM, FRET-based sensor for CaMKII activity (FRESCA): A useful tool for assessing CaMKII activity in response to Ca<sup>2+</sup> oscillations in live cells. *J. Biol. Chem* 294, 11876–11891 (2019). [PubMed: 31201271]
36. Kostyuk AI, Demidovich AD, Kotova DA, Belousov VV, Bilan DS, Circularly permuted fluorescent protein-based indicators: History, principles, and classification. *Int. J. Mol. Sci* 20, 4200 (2019). [PubMed: 31461959]
37. Mehta S, Zhang Y, Roth RH, Zhang J, Mo A, Tenner B, Huganir RL, Zhang J, Single-fluorophore biosensors for sensitive and multiplexed detection of signalling activities. *Nat. Cell Biol* 20, 1215–1225 (2018). [PubMed: 30250062]
38. Zhang J-F, Liu B, Hong I, Mo A, Roth RH, Tenner B, Lin W, Zhang JZ, Molina RS, Drobizhev M, Hughes TE, Tian L, Huganir RL, Mehta S, Zhang J, An ultrasensitive biosensor for high-resolution kinase activity imaging in awake mice. *Nat. Chem. Biol* 17, 39–46 (2021). [PubMed: 32989297]
39. Levy DE, Schulman H, Paraselli BR, Kumar NS, Dabbugoddu B, Balasubramanyam C, CaMKII inhibitors and uses thereof, U.S. Patent 20170247374-A1 (2017).
40. Levy DE, Schulman H, Paraselli BR, Kumar NS, Dabbugoddu B, Balasubramanyam C, CaMKII inhibitors and uses thereof, U.S. Patent 20200385383-A1 (2020).
41. Bajar BT, Wang ES, Lam AJ, Kim BB, Jacobs CL, Howe ES, Davidson MW, Lin MZ, Chu J, Improving brightness and photostability of green and red fluorescent proteins for live cell imaging and FRET reporting. *Sci. Rep* 6, 20889 (2016). [PubMed: 26879144]
42. Punwani N, Yeleswaram S, Chen X, Bowman J, Soloviev M, Williams W, Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study. *Clin. Pharmacol. Drug Dev* 3, 207–214 (2014). [PubMed: 27128611]
43. Zhao X, Sheng XY, Payne CD, Zhang X, Wang F, Cui YM, Pharmacokinetics, safety, and tolerability of single- and multiple-dose once-daily baricitinib in healthy Chinese subjects: A randomized placebo-controlled study. *Clin. Pharmacol. Drug Dev* 9, 952–960 (2020). [PubMed: 32945153]
44. Zhong B, Campagne O, Salloum R, Purzner T, Stewart CF, LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci* 1152, 122254 (2020).
45. Panetta JC, Baker SD, Kantarjian HM, Stewart C, Pond B, Macaraeg M, Makinde T, Vali S, Daver N, Ramachandran A, Collins R, Cortes JE, Population pharmacokinetics of crenolanib, a type I FLT3 inhibitor, in patients with relapsed/refractory AML. *Blood* 126, 3695 (2015).
46. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI, Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discov.* 6, 740–753 (2016). [PubMed: 27217383]

47. Movsesian MA, Nishikawa M, Adelstein RS, Phosphorylation of phospholamban by calcium-activated, phospholipid-dependent protein kinase. Stimulation of cardiac sarcoplasmic reticulum calcium uptake. *J. Biol. Chem* 259, 8029–8032 (1984). [PubMed: 6234308]
48. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR, Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. *J. Biol. Chem* 261, 13333–13341 (1986). [PubMed: 3759968]
49. Mattiazzi A, Kranias E, The role of CaMKII regulation of phospholamban activity in heart disease. *Front. Pharmacol* 5, 5 (2014). [PubMed: 24550830]
50. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. *Blood* 115, 3109–3117 (2010). [PubMed: 20130243]
51. Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegano C, Schinazi RF, Poznansky MC, Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. *Oncotarget* 8, 94040–94053 (2017). [PubMed: 29212208]
52. Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, Cheng C, Kurachi M, Levine R, Wherry EJ, Canna SW, Behrens EM, Nichols KE, Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. *Blood* 127, 1666–1675 (2016). [PubMed: 26825707]
53. Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM, Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. *Blood* 135, 1062–1066 (2020). [PubMed: 32047890]
54. Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R, Nichols KE, Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. *Blood* 134, 147–159 (2019). [PubMed: 31015190]
55. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG, Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C<sup>+/-</sup>) mice with catecholaminergic polymorphic ventricular tachycardia. *J. Mol. Cell. Cardiol* 50, 214–222 (2011). [PubMed: 20937285]
56. Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Sood S, Kearney DL, Danila CI, De Biasi M, Wehrens XHT, Pautler RG, Roden DM, Taffet GE, Dirksen RT, Anderson ME, Hamilton SL, Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. *Proc. Natl. Acad. Sci. U.S.A* 103, 12179–12184 (2006). [PubMed: 16873551]
57. Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, Santonastasi M, Müller FU, Schmitz W, Schotten U, Anderson ME, Valderrábano M, Dobrev D, Wehrens XHT, Calmodulin kinase II-mediated sarcoplasmic reticulum Ca<sup>2+</sup> leak promotes atrial fibrillation in mice. *J. Clin. Invest* 119, 1940–1951 (2009). [PubMed: 19603549]
58. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, Stefansdottir H, Behunin AC, Li N, El-Accaoui RN, Yang B, Swaminathan PD, Weiss RM, Wehrens XHT, Song L-S, Dobrev D, Maier LS, Anderson ME, Oxidized Ca<sup>2+</sup>/calmodulin-dependent protein kinase II triggers atrial fibrillation. *Circulation* 128, 1748–1757 (2013). [PubMed: 24030498]
59. Mesubi OO, Rokita AG, Abrol N, Wu Y, Chen B, Wang Q, Granger JM, Tucker-Bartley A, Luczak ED, Murphy KR, Umapathi P, Banerjee PS, Boronina TN, Cole RN, Maier LS, Wehrens XH, Pomerantz JL, Song L-S, Ahima RS, Hart GW, Zachara NE, Anderson ME, Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. *J. Clin. Invest* 131, e95747 (2021). [PubMed: 33151911]
60. Kannel WB, Abbott RD, Savage DD, McNamara PM, Epidemiologic features of chronic atrial fibrillation: The Framingham study. *N. Engl. J. Med* 306, 1018–1022 (1982). [PubMed: 7062992]
61. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM, Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. *Nature* 502, 372–376 (2013). [PubMed: 24077098]


62. Umapathi P, Banerjee PS, Zachara NE, Abrol N, Wang Q, Mesubi OO, Luczak ED, Wu Y, Granger JM, Wei A-C, Reyes Gaido OE, Florea L, Talbot CC Jr., Hart GW, Anderson ME, Excessive *O*-GlcNAcylation causes heart failure and sudden death. *Circulation* 143, 1687–1703 (2021). [PubMed: 33593071]
63. Müller FU, Lewin G, Baba HA, Boknik P, Fabritz L, Kirchhefer U, Kirchhof P, Loser K, Matus M, Neumann J, Riemann B, Schmitz W, Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. *J. Biol. Chem* 280, 6906–6914 (2005). [PubMed: 15569686]
64. Li N, Chiang DY, Wang S, Wang Q, Sun L, Voigt N, Respress JL, Ather S, Skapura DG, Jordan VK, Horrigan FT, Schmitz W, Müller FU, Valderrabano M, Nattel S, Dobrev D, Wehrens XHT, Ryanodine-receptor mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. *Circulation* 129, 1276–1285 (2014). [PubMed: 24398018]
65. Bayer KU, Schulman H, CaM kinase: Still inspiring at 40. *Neuron* 103, 380–394 (2019). [PubMed: 31394063]
66. Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, Rupa M, Behshad E, Gardiner C, Collier P, Liu P, Burn T, Wynn R, Hollis G, Yeleswaram S, The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy. *Drug Metab. Dispos* 42, 1656–1662 (2014). [PubMed: 25063672]
67. Plosker GL, Ruxolitinib: A review of its use in patients with myelofibrosis. *Drugs* 75, 297–308 (2015). [PubMed: 25601187]
68. Wang H, Feng R, Wang LP, Li F, Cao X, Tsien JZ, CaMKII activation state underlies synaptic labile phase of LTP and short-term memory formation. *Curr. Biol* 18, 1546–1554 (2008). [PubMed: 18929487]
69. Bach ME, Hawkins RD, Osman M, Kandel ER, Mayford M, Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the  $\theta$  frequency. *Cell* 81, 905–915 (1995). [PubMed: 7781067]
70. Zalzman G, Federman N, Romano A, CaMKII isoforms in learning and memory: Localization and function. *Front. Mol. Neurosci* 11, 445 (2018). [PubMed: 30564099]
71. Wang H, Shimizu E, Tang Y-P, Cho M, Kyin M, Zuo W, Robinson DA, Alaimo PJ, Zhang C, Morimoto H, Zhuo M, Feng R, Shokat KM, Tsien JZ, Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. *Proc. Natl. Acad. Sci. U.S.A* 100, 4287–4292 (2003). [PubMed: 12646704]
72. Moriguchi S, Tagashira H, Sasaki Y, Yeh JZ, Sakagami H, Narahashi T, Fukunaga K, CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment. *J. Neurochem* 128, 927–937 (2014). [PubMed: 24164423]
73. Bachstetter AD, Webster SJ, Tu T, Goulding DS, Haiech J, Watterson DM, Van Eldik LJ, Generation and behavior characterization of CaMKII $\beta$  knockout mice. *PLOS ONE* 9, e105191 (2014). [PubMed: 25127391]
74. Federman N, de la Fuente V, Zalzman G, Corbi N, Onori A, Passananti C, Romano A, Nuclear factor  $\kappa$ B-dependent histone acetylation is specifically involved in persistent forms of memory. *J. Neurosci* 33, 7603–7614 (2013). [PubMed: 23616565]
75. Nair AB, Jacob S, A simple practice guide for dose conversion between animals and human. *J. Basic Clin. Pharm* 7, 27–31 (2016). [PubMed: 27057123]
76. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. *N. Engl. J. Med* 363, 1117–1127 (2010). [PubMed: 20843246]
77. Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue T-Y, Yeleswaram S, Metabolism, excretion, and pharmacokinetics of [<sup>14</sup>C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. *Drug Metab. Dispos* 38, 2023–2031 (2010). [PubMed: 20699411]
78. Haile WB, Gavegnano C, Tao S, Jiang Y, Schinazi RF, Tyor WR, The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. *Neurobiol. Dis* 92, 137–143 (2016). [PubMed: 26851503]

79. van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers DM, Wehrens XHT, Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. *Circulation* 122, 2669–2679 (2010). [PubMed: 21098440]
80. Pan X, Philippen L, Lahiri SK, Lee C, Park SH, Word TA, Li N, Jarrett KE, Gupta R, Reynolds JO, Lin J, Bao G, Lagor WR, Wehrens XHT, In vivo *Ryr2* editing corrects catecholaminergic polymorphic ventricular tachycardia. *Circ. Res* 123, 953–963 (2018). [PubMed: 30355031]
81. Park S-J, Zhang D, Qi Y, Li Y, Lee KY, Bezzerides VJ, Yang P, Xia S, Kim SL, Liu X, Lu F, Pasqualini FS, Campbell PH, Geva J, Roberts AE, Kleber AG, Abrams DJ, Pu WT, Parker KK, Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue. *Circulation* 140, 390–404 (2019). [PubMed: 31311300]
82. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM, Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. *Br. J. Haematol* 189, 888–903 (2020). [PubMed: 32017044]
83. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators, Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *J. Hematol. Oncol* 10, 55 (2017). [PubMed: 28228106]
84. Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S, The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. *J. Clin. Pharmacol* 51, 1644–1654 (2011). [PubMed: 21257798]
85. Dobrev D, Aguilar M, Heijman J, Guichard J-B, Nattel S, Postoperative atrial fibrillation: Mechanisms, manifestations and management. *Nat. Rev. Cardiol* 16, 417–436 (2019). [PubMed: 30792496]
86. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT; for the Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group, A multicenter risk index for atrial fibrillation after cardiac surgery. *JAMA* 291, 1720–1729 (2004). [PubMed: 15082699]
87. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, Armstrong PW, Granger CB; for the APEX AMI Investigators, Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. *JAMA* 301, 1779–1789 (2009). [PubMed: 19417195]
88. Heijman J, Muna AP, Veleva T, Molina CE, Sutanto H, Tekook M, Wang Q, Abu-Taha IH, Gorka M, Künzel S, El-Armouche A, Reichenspurner H, Kamler M, Nikolaev V, Ravens U, Li N, Nattel S, Wehrens XHT, Dobrev D, Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation. *Circ. Res* 127, 1036–1055 (2020). [PubMed: 32762493]
89. Bell JR, Vila-Petroff M, Delbridge LMD, CaMKII-dependent responses to ischemia and reperfusion challenges in the heart. *Front. Pharmacol* 5, 96 (2014). [PubMed: 24834054]
90. Tsuji Y, Hojo M, Voigt N, El-Armouche A, Inden Y, Murohara T, Dobrev D, Nattel S, Kodama I, Kamiya K, Ca<sup>2+</sup>-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. *Circulation* 123, 2192–2203 (2011). [PubMed: 21555709]
91. Roston TM, Jones K, Hawkins NM, Bos JM, Schwartz PJ, Perry F, Ackerman MJ, Laksman ZWM, Kaul P, Lieve KVV, Atallah J, Krahn AD, Sanatani S, Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. *Heart Rhythm* 15, 1791–1799 (2018). [PubMed: 30063211]
92. Mishra S, Sadagopan N, Dunkerly-Eyring B, Rodriguez S, Sarver DC, Ceddia RP, Murphy SA, Knutsdotir H, Jani VP, Ashok D, Oeing CU, O'Rourke B, Gangoiti JA, Sears DD, Wong GW,



- Collins S, Kass DA, Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. *J. Clin. Invest* 131, e148798 (2021). [PubMed: 34618683]
93. Pavlaki N, De Jong KA, Geertz B, Nikolaev VO, Froese A, Cardiac hypertrophy changes compartmentation of cAMP in non-raft membrane microdomains. *Cell* 10, 535 (2021).
  94. Eid S, Turk S, Volkamer A, Rippmann F, Fulle S, KinMap: A web-based tool for interactive navigation through human kinome data. *BMC Bioinformatics* 18, 16 (2017). [PubMed: 28056780]
  95. Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL, Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database. *Ann. Rheum. Dis* 81, 335–343 (2022). [PubMed: 34706874]
  96. Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M, Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. *Oncologist* 26, e53–e65 (2021). [PubMed: 32955138]
  97. Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP, MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *Npj Breast Cancer* 5, 5 (2019). [PubMed: 30675515]
  98. Borad MJ, Bai L-Y, Chen M-H, Hubbard JM, Mody K, Rha SY, Richards DA, Davis SL, Soong J, Huang C-EC-E, Tse E, Ahn DH, Chang H-M, Yen C-J, Oh D-Y, Park JO, Hsu C, Becerra CR, Chen J-S, Chen Y-Y, Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. *J. Clin. Oncol* 39, 312–312 (2021).
  99. Wang ES, Goldberg AD, Walter RB, Collins R, Stone RM, Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML. *J. Clin. Oncol* 40, 7007–7007 (2022).
  100. Wu M, Li C, Zhu X, FLT3 inhibitors in acute myeloid leukemia. *J. Hematol. Oncol* 11, 133 (2018). [PubMed: 30514344]
  101. Incyte Corporation, JAKAFI (ruxolitinib) tablets, for oral use [package insert]; [www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/202192s0231bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202192s0231bl.pdf).
  102. Eli Lilly and Company, OLUMIANT (baricitinib) tablets, for oral use; [www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/207924s0061bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s0061bl.pdf).
  103. Jorgensen SCJ, Tse CLY, Burry L, Dresser LD, Baricitinib: A review of pharmacology, safety, and emerging clinical experience in COVID-19. *Pharmacotherapy* 40, 843–856 (2020). [PubMed: 32542785]
  104. Eli Lilly and Company, VERZENIO (abemaciclib) tablets, for oral use; [www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/208716s006s007s0081bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s0081bl.pdf).
  105. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M, Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. *Blood* 123, 94–100 (2014). [PubMed: 24227820]
  106. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; on behalf of the monarchE Committee Members and Investigators, Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR<sup>+</sup>, HER2<sup>-</sup>, node-positive, high-risk, early breast cancer (monarchE). *J. Clin. Oncol* 38, 3987–3998 (2020). [PubMed: 32954927]
  107. Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cortes JE, Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations. *Blood* 124, 389 (2014).


108. Gavegnano C, Haile WB, Hurwitz S, Tao S, Jiang Y, Schinazi RF, Tyor WR, Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. *J. Neuroinflammation* 16, 182 (2019). [PubMed: 31561750]
109. Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, Dios AD, Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. *Drug Metab. Dispos* 43, 1360–1371 (2015). [PubMed: 26149830]
110. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050. *J. Immunol* 184, 5298–5307 (2010). [PubMed: 20363976]
111. Jiang J, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen D-T, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ, Examining the chirality, conformation and selective kinase inhibition of 3-((3*R*,4*R*)-4-methyl-3-(methyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). *J. Med. Chem* 51, 8012–8018 (2008). [PubMed: 19053756]
112. Ito M, Yamazaki S, Yamagami K, Kuno M, Morita Y, Okuma K, Nakamura K, Chida N, Inami M, Inoue T, Shirakami S, Higashi Y, A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. *J. Pharmacol. Sci* 133, 25–33 (2017). [PubMed: 28117214]
113. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. *Cancer Cell* 13, 311–320 (2008). [PubMed: 18394554]
114. Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, tvan ' Klooster G, Feyen JHM, Menet C, Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. *J. Immunol* 191, 3568–3577 (2013). [PubMed: 24006460]
115. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U, The novel kinase inhibitor PRT062070 (cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. *J. Pharmacol. Exp. Ther* 351, 538–548 (2014). [PubMed: 25253883]
116. Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP, Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. *Blood Cancer J.* 3, e109 (2013). [PubMed: 23584399]
117. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A, CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. *Leukemia* 23, 1441–1445 (2009). [PubMed: 19295546]
118. Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M, Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. *J. Vet. Pharmacol. Ther* 37, 317–324 (2014). [PubMed: 24495176]



**Fig. 1. CaMKAR is a sensitive and specific CaMKII activity reporter.**


(A) Schematic depiction of CaMKII activity reporter (CaMKAR). PAABD, phosphorylated amino acid binding domain). The phospho-substrate threonine is shown in red. Upon phosphorylation by CaMKII, the substrate is bound by the PAABD, which enables conformational reconstitution of GFP fluorescence: 488-nm emission is increased, whereas 405-nm emission is unchanged. (B) Fluorescence confocal microscopy of CaMKAR-expressing HEK293T cells treated with ionomycin (5  $\mu$ M).  $R$ , ratio of 488 nm-excited (green) and 405 nm-excited intensities (gray). Scale bars, 20  $\mu$ m. The third row is pseudo-colored to display fold change over baseline. (C) Summary data for the CaMKAR signal in HEK293T cells over time treated with vehicle only (black,  $n$  = 2488 to 2615 cells) or ionomycin (iono; magenta; 5  $\mu$ M;  $n$  = 1733 to 2220 cells), pretreatment with the CaMKII inhibitor AS100397 (purple, 10  $\mu$ M;  $n$  = 1305 to 1348 cells), or posttreatment with EGTA (teal, 5 mM;  $n$  = 1474 to 1746). No exogenous CaMKII was added.  $R/R_0$ ,  $R$  normalized to mean baseline. Arrows denote administration time. (D) CaMKAR signal in HEK293T cells expressing doxycycline-inducible wild type (WT), kinase dead (KD; K43M mutation), or constitutively active (CA; T287D mutation) CaMKII $\delta_C$  compared with vehicle-treated.  $N$  = 3 wells per condition. (E) deadCaMKAR(T6A mutant) signal over time in HEK293T cells coexpressing WT ( $n$  = mean of three wells), CA ( $n$  = mean of three wells), kinase

dead CaMKII $\delta_C$  (KD;  $n$  = mean of three wells), or empty vector ( $n$  = mean of three wells) and then stimulated with ionomycin. (F) CaMKAR signal in CaMKAR-expressing HEK293T cells cotransfected with CA CaMKI ( $n$  = 1471 cells), CaMKIV ( $n$  = 1732 cells), or CaMKII $\delta$  ( $n$  = 1816 cells). (G) CaMKAR signal in CaMKAR-expressing HEK293T cells treated with forskolin (Fsk; 50  $\mu$ M)/IBMX (100  $\mu$ M;  $n$  = 1834 to 1891 cells) or ionomycin ( $n$  = 1997 to 2293). (H) CaMKAR signal in CaMKAR-expressing HEK293T cells treated with PMA (100 ng/ml;  $n$  = 696 to 737 cells) or ionomycin (5  $\mu$ M;  $n$  = 767 to 916). (I) CaMKAR signal in CaMKAR-expressing HEK293T cells treated with PDBu (200 nM;  $n$  = 1706 to 1736 cells) or ionomycin (5  $\mu$ M;  $n$  = 1206 to 1228). For (G to I), arrows denote administration time of either ionomycin or one of Fsk/IBMX, PMA, and PDBu. Data are shown as means  $\pm$  SEM (error is not displayed whenever it is smaller than the data point). All observations are taken from more than three biological replicates. ns,  $P > 0.05$  and \*\*\*\* $P < 0.0001$ ; significance was determined via two-way analysis of variance (ANOVA) and Šidák's multiple comparisons test (D and G to I), linear regression (E), and one-way ANOVA with Dunnett's multiple comparisons test (F).



**Fig. 2. CaMKAR-based screen identifies CaMKII inhibitors among drugs in clinical use.** (A) Schematic depiction of CaMKAR-based high-throughput screen. K562 cells were coinfecting with CaMKAR- and CA CaMKII<sup>T287D</sup>-encoding lentiviruses. CaMKII expression could be induced with doxycycline. K562<sup>CaMKII-CaMKAR</sup> cells were screened against the Johns Hopkins Drug Library v3.0. Primary hits were further screened using in vitro assays to eliminate false positives and narrow the list to five CaMKII inhibitors. (B) Drugs ranked according to in cellulo CaMKII inhibition in primary screen. CaMKII inhibition percentage defined by minimum-maximum normalization using means of control groups [CTRL (untreated) and AS100397; same data as fig. S4B]. A total of 118 selected hits are shown in blue. Positive control staurosporine is shown in magenta. The dashed line represents hit selection threshold (see Materials and Methods). Data shown are subsets (those scoring between 0 and 140% for visualization of hits) from the complete dataset in data file S1. (C) Hits from (B) ranked according to in vitro CaMKII inhibition as detected by CaMKAR secondary screen. CaMKII inhibition normalized against untreated control (CTRL). AS100397 was used as a positive control. Thirteen identified hits are in blue. Staurosporine is shown in magenta. Data shown are subsets from the complete dataset (see Supplementary Materials). (D) Five CaMKII inhibitory drugs and their intended targets within the human kinase homology dendrogram. Kinase families: AGC, containing PKA, PKG, and PKC families; CK1, casein kinase 1; CMGC, containing CDK, MAPK, GSK3, and CLK; STE, homologs of yeast sterile 7, sterile 11, and sterile 20; TK, tyrosine kinase; TKL, tyrosine kinase-like. (E) IC<sub>50</sub> (left) and cell viability (right) curves from 293T cells expressing CaMKAR and CaMKII<sup>T287D</sup> and exposed to five candidate drugs and CaMKII inhibitor (AS100397, 10 mM). Measurements in (E) are done in biological triplicate; complete dataset is shown in fig. S5.





**Fig. 3. CaMKAR indicates that drugs in clinical use inhibit CaMKII in CMs.**

(A) Fluorescence imaging time lapse (0, 30, and 60 s) of CaMKAR-expressing neonatal rat ventricular CMs (NRVMs) and (B) summary data during 3-Hz field pacing ( $n = 1065$  to 1160 cells).  $R$ , ratio of 488 nm-excited and 405 nm-excited intensities. Third row of images is pseudo-colored to display fold change over baseline.  $R/R_0$ ,  $R$  normalized to mean  $R$  before stimulation. Scale bars, 50  $\mu\text{m}$ . (C) Effect of treatment with vehicle ( $n = 317$  cells), AS100397 ( $n = 151$ ), ruxolitinib ( $n = 148$ ), crenolanib ( $n = 156$ ), abemaciclib ( $n = 138$ ), baricitinib ( $n = 136$ ), and silmitasertib ( $n = 149$ ) on pacing-induced CaMKII activity in NRVMs. CaMKII inhibition percentage defined by minimum-maximum normalization between untreated and maximally stimulated CaMKAR signal. (D) CaMKII inhibition over time in NRVMs treated with drugs adjusted to their maximum human plasma concentrations during 3-Hz pacing: ruxolitinib (1.51  $\mu\text{M}$ ,  $n = 384$  cells), crenolanib (478 nM,  $n = 302$ ), abemaciclib (243 nM,  $n = 302$ ), baricitinib (58 nM,  $n = 334$ ), and silmitasertib (3.42  $\mu\text{M}$ ,  $n = 285$ ). The arrow indicates start of pacing. (E) Summary data from (D) at 60 s after stimulation. (F) Analysis of CaMKII activity based on CaMKAR time-lapse imaging in NRVMs treated with ruxolitinib after initiation of pacing and CaMKII activation. Black arrow denotes pacing start; blue arrow denotes addition of ruxolitinib ( $n = 3$  wells) or control vehicle ( $n = 3$  wells). (G)  $\text{IC}_{50}$  curves for ruxolitinib ( $n = 308$  to 384 per data point) and DiOHF ( $n = 305$  to 363) in NRVMs against pacing-induced CaMKII activity. (H) Cell viability after 48-hour compound incubation. All measurements were taken from more than three biological replicates. ns,  $P > 0.05$  and \*\*\*\*  $P < 0.0001$ ; significance determined via


one-way ANOVA and Dunnett's multiple comparisons test (C and E) and two-way ANOVA and Tukey's multiple comparisons test (F).

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Fig. 4. Ruxolitinib inhibits CaMKII in vivo.**

(A) Immunoblot and (B to C) quantitation of phospholamban (PLN; pentameric or monomer) and threonine-17-phosphorylated phospholamban in whole-heart lysates from mice treated with intraperitoneal ruxolitinib (Rux) for 10 min before isoproterenol (ISO) stimulation. P, pentameric PLN; M, monomeric PLN. Data points represent individual mice. \*\*\*\* $P < 0.0001$ ; significance determined via one-way ANOVA and Tukey's multiple comparisons test.




**Fig. 5. Ruxolitinib suppresses abnormal calcium signaling in a cellular model of CPVT.** iPSCs with the dominant *RYR2* mutation (p.S404R) were generated from a patient with a clinical diagnosis of CPVT (*RYR2*<sup>S404R/WT</sup>) and differentiated into functional CMs (iPSC-CMs). After plating on glass-bottom dishes, *RYR2*<sup>S404R/WT</sup> and WT iPSC-CMs were loaded with the fluorescent Ca<sup>2+</sup> indicator (Fluo-4) and electrically paced at 1 Hz for 10 s. (A) Representative tracings of calcium transients in WT and *RYR2*<sup>S404R/WT</sup> cells. The appearance of aCREs after the cessation of pacing is indicative of deranged Ca<sup>2+</sup> signaling in CPVT iPSC-CMs (right). Raw data are in blue, and filtered data are in orange overlay. (B) Quantification of aCREs over 20 s in WT and *RYR2*<sup>S404R/WT</sup> iPSC-CMs with preincubation of 2 μM ruxolitinib compared with vehicle alone (DMSO). (C to F) Automated analysis of Ca<sup>2+</sup> transient parameters during 1-Hz pacing of iPSC-CMs for mean amplitude (C), Ca<sup>2+</sup> transient duration at 50% of peak amplitude (TCa<sub>50</sub>) (D), upstroke velocity (E), and downstroke velocity (F). The numbers of analyzed cells (*n*) are annotated on each graph and were from at least two independent differentiations and four separate culture wells. Statistics were performed by one-way Kruskal-Wallis with Dunn's multiple comparisons test: ns, *P* > 0.1; \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.005; and \*\*\*\**P* < 0.0001.



**Fig. 6. Ruxolitinib prevents arrhythmias in a murine model of CPVT.**


Isolated adult murine CMs from mice with the pathogenic CPVT variant *RyR2*<sup>R176Q/WT</sup> were loaded with the calcium indicator Rhod-2 and paced for 30 s at 1 Hz. (A) Representative tracings of calcium transients in WT and *RyR2*<sup>R176Q/WT</sup> CMs treated with DMSO or ruxolitinib. (B) Quantification of aCRE frequency over 20 s for WT and *RyR2*<sup>R176Q/WT</sup> CMs after preincubation with 2  $\mu$ M ruxolitinib (or DMSO). (C) Animals were treated with ruxolitinib (75 mg/kg) or vehicle by intraperitoneal injection and then subjected to programmed ventricular extrastimulus testing. Representative traces of induced ventricular arrhythmias *RyR2*<sup>R176Q/WT</sup> animals with vehicle- but not in ruxolitinib-treated mice. (D) Quantification of animals with ventricular arrhythmias (VF/VT) in WT and *RyR2*<sup>R176Q/WT</sup> animals with vehicle or ruxolitinib treatment after concurrent stimulation with isoproterenol (2 mg/kg) and epinephrine (4 mg/kg). (E) Quantification of the duration of arrhythmias induced by ventricular pacing in WT and *RyR2*<sup>R176Q/WT</sup> animals with vehicle or ruxolitinib treatment. Number of animals in each group (*N*): *N* = 13 (WT + DMSO), *N* = 10 (WT + ruxolitinib), *N* = 13 (*RyR2*<sup>R176Q/WT</sup> + DMSO), and *N* = 15 (*RyR2*<sup>R176Q/WT</sup> + ruxolitinib). Statistics were performed by one-way Kruskal-Wallis with Dunn's multiple comparisons test, for continuous variables or chi-squared for discrete variables: ns, *P* > 0.1; \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.005; and \*\*\*\**P* < 0.0001.





**Fig. 7. Ruxolitinib prevents and rescues AF in mice.**

(A) Representative type 1 diabetic mouse tracings immediately after atrial burst pacing. DMSO-treated mice demonstrate AF (top), whereas ruxolitinib (Rux)-treated mice (75 mg/kg; single dose 10 min before, intraperitoneal) retain sinus rhythm (bottom). (B) AF inducibility percentage from mice in (A). The total number of mice analyzed per group is shown in each column: Nine of 16 vehicle-treated mice had AF versus 2 of 15 Rux-treated mice. (C) Sequential AF (AF) inducibility in OGT-transgenic mice. Mice were treated with vehicle immediately before AF induction; the same mice were then treated with ruxolitinib (75 mg/kg) before pacing for a second time. The number of mice analyzed per group is shown in each column (vehicle, five of five had AF; Rux, one of five had AF). (D) Percentage of time in AF or sinus rhythm (for 10 to 25 min after treatment administration) in CREM-Ib C-X mice when treated with vehicle (baseline) or when treated with ruxolitinib (75 mg/kg) 24 hours later ( $n = 9$ , paired). (E) Individual trajectories of percentage of time in AF (for 10 to 25 min after treatment) in same mice as in (D) ( $n = 9$ , paired). Statistical comparisons were performed using two-tailed Fischer's exact test (B and C), two-way ANOVA with Šidák's multiple comparison's test (D), and paired Student's  $t$  test (E);  $*P < 0.05$  and  $****P < 0.0001$ .



**Fig. 8. Ruxolitinib does not impair short-term or spatial memory in mice.**

(A) WT C57BL/6J mice were treated with a single dose (1 hour before) or multiple doses (7 days, twice daily) of ruxolitinib before behavioral testing via the NORT and the Y maze spatial recognition memory test. (B and C) Percentage of time spent with novel object. (D and E) Total distance traveled while in the testing chamber. (F and G) Percentage of time spent in novel arm of Y maze. Each data point represents a mouse ( $n = 7$  to 10 mice for all conditions). ns,  $P > 0.05$  and  $*P < 0.05$ ; significance was determined by one-way ANOVA and Tukey's multiple comparisons test.